Home
- Destinations
- Vaccinations
- News & Announcements
- Travel Notices
- Diseases
- Yellow Book
- Find a Clinic
- Specific Groups & Settings
- Seasonal Flu & Travel
- Earthquake, Tsunami, and Radiation Release in Japan: Travel Information
- Traveling with Children
- Special Needs
- Disaster Relief
- Avian Flu & Travel
- Air & Cruise Ship Travel
- Air Travel Information For Travelers
- Cruise Ship Information for Travelers
- For Industry: Air
- CDC Measles Guidance for Commercial Aircraft Operators
- Interim Guidance for Protecting Travelers on Commercial Aircraft Serving Haiti During the Cholera Outbreak
- Reporting Onboard Deaths or Illnesses to CDC
- Onboard Death and Illness Response Tool for Cabin Crew
- Onboard Death and Illness Reporting Tool for Pilots
- CDC Guidance for Commercial Aircraft Operators: Seasonal Influenza
- Infection Control Guidelines for Cabin Crew Members on Commercial Aircraft
- For Industry: Cruise Ships
- Stay Healthy & Safe
- Illness & Injury Abroad
- Resources & Training
- Travel Podcasts
- RSS Feeds
Chapter 3Infectious Diseases Related To Travel
Cyclosporiasis
David R. Shlim, Barbara L. Herwaldt
INFECTIOUS AGENT
Cyclosporiasis is caused by Cyclospora cayetanensis, which is a protozoan (unicellular), coccidian parasite; oocysts (rather than cysts) are shed in the feces of infected people.
MODE OF TRANSMISSION
Infection results from ingestion of mature (infective) Cyclospora oocysts, such as in contaminated food or water. Direct person-to-person transmission is unlikely, because the oocysts shed in feces must mature in the environment (outside the host) to become infective to someone else. Limited data indicate that the maturation process requires from days to weeks in favorable conditions.
EPIDEMIOLOGY
Cyclosporiasis appears to be most common in tropical and subtropical regions of the world. Outbreaks in the United States and Canada have been linked to various types of imported fresh produce. People of all ages are at risk for infection, and travelers to developing countries can be at increased risk. In some regions where cyclosporiasis has been studied, the risk for infection is seasonal. However, no consistent pattern has been discerned with respect to time of year or environmental conditions.
CLINICAL PRESENTATION
Cyclospora infects the small intestine. Asymptomatic infection has been documented, particularly in settings where cyclosporiasis is endemic. Among symptomatic people, the incubation period averages 1 week (range, 2 days to more than 2 weeks). Onset of symptoms is often abrupt but can be gradual; some people have an influenzalike prodrome. The most common symptom is watery diarrhea, which can be profuse. Other common symptoms include anorexia, weight loss, abdominal cramps, bloating, nausea, and body aches. Vomiting and low-grade fever may be noted. If untreated, the illness can last for several weeks or months, with a remitting-relapsing course and prolonged fatigue and malaise.
DIAGNOSIS
Infection is diagnosed by detecting Cyclospora oocysts (8–10 µm in diameter) in stool specimens. Stool examinations for ova and parasites usually do not include methods for detecting Cyclospora. Therefore, clinicians should specifically request testing for this parasite. Cyclospora oocysts commonly are shed at low levels, even by people with profuse diarrhea. This constraint underscores the utility of repeated stool examinations, sensitive recovery methods (particularly concentration procedures), and detection methods that highlight the organism. Cyclospora oocysts autofluoresce when viewed by UV fluorescence microscopy and can be stained with modified acid-fast or modified (“hot”) safranin techniques; these techniques can be used as detection methods for Cyclospora. For more information about these and other laboratory methods, visit the CDC website at www.dpd.cdc.gov/dpdx/HTML/Cyclosporiasis.htm. Diagnostic assistance is also available from CDC (see contact information below).
TREATMENT
The treatment of choice is trimethoprim-sulfamethoxazole (TMP-SMX). The typical regimen for immunocompetent adults is TMP 160 mg plus SMX 800 mg (1 double-strength tablet), orally, twice per day for 7–10 days. No highly effective alternatives have been identified for people allergic to (or intolerant of) TMP-SMX. Clinicians may consult CDC about possible approaches for such people (CDC Parasitic Diseases Public Inquiries, 404-718-4745; parasites@cdc.gov). Additional information about clinical issues can be found at www.cdc.gov/parasites/cyclosporiasis.
PREVENTIVE MEASURES FOR TRAVELERS
No vaccine is available. Travelers to developing countries should follow the precautions described in Chapter 2, Food and Water Precautions. Disinfection with chlorine or iodine is unlikely to be effective against Cyclospora oocysts.
BIBLIOGRAPHY
- Herwaldt BL. Cyclospora cayetanensis: a review, focusing on the outbreaks of cyclosporiasis in the 1990s. Clin Infect Dis. 2000 Oct;31(4):1040–57.
- Shlim DR. Cyclospora cayetanensis. Clin Lab Med. 2002 Dec;22(4):927–36.
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - New Hours of Operation
8am-8pm ET/Monday-Friday
Closed Holidays - Contact CDC-INFO